HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis.

AbstractBACKGROUND AND METHODS:
We examined the outcomes of synovial sarcoma (SS) patients in a national database. We identified 1,189 patients from the Surveillance, Epidemiology, and End Results (SEER) database with data on site and extent of surgery. We excluded patients diagnosed before 1990, <18 years, or lacking pathologic confirmation. Using Kaplan-Meier and Cox proportional hazards analyses, we determined predictors of overall (OS) and disease-specific survival (DSS).
RESULTS:
The mean age was 41, 49.3% were female, and 82.2% were white. Radiotherapy (RT) was administered to 57.5%. On multivariable analysis, age at diagnosis, sex, race, anatomic site, SEER summary stage, tumor size, surgery type, and RT predicted OS. Similar predictors of DSS were identified. The hazard ratio (HR) for OS was 0.65 (95% CI 0.48-0.88) in favor of RT and 0.62 (95% CI 0.45-0.86) for DSS. Five-year OS improved 8.4 ± 1.0% with RT (P=0.003), and five-year DSS improved 7.7 ± 1.0% with RT (P=0.015).
CONCLUSIONS:
In the largest study to date examining the role of RT in synovial sarcoma, we observed that RT was associated with a statistically significant improvement in oncologic outcome among SS patients. These data support the use of RT in the multi-modality treatment of patients with SS.
AuthorsKhatija W Naing, Arta M Monjazeb, Chin-Shang Li, Li-Yuan Lee, Anthony Yang, Dariusz Borys, Robert J Canter
JournalJournal of surgical oncology (J Surg Oncol) Vol. 111 Issue 2 Pg. 158-64 (Feb 2015) ISSN: 1096-9098 [Electronic] United States
PMID25176165 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Copyright© 2014 Wiley Periodicals, Inc.
Topics
  • Adult
  • Age Factors
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Male
  • Multivariate Analysis
  • Neoplasm Grading
  • Racial Groups
  • Radiotherapy, Adjuvant
  • SEER Program
  • Sarcoma, Synovial (mortality, pathology, therapy)
  • Sex Factors
  • Soft Tissue Neoplasms (mortality, pathology, therapy)
  • United States (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: